

# BOLETÍN AFinf

Actualización en terapéutica antimicrobiana y enfermedades infecciosas

Grupo de trabajo AFinf – Sociedad Española de Farmacia Hospitalaria

**Volumen 4 N° 2-Julio de 2019**

## Contenido:

- Actualización farmacoterapéutica.
- Guías de práctica clínica, documentos consenso.
- Alertas farmacéuticas.
- IPT
- Información a pacientes.
- APPs

---

## Actualización farmacoterapéutica

- **Indicadores del uso hospitalario de antimicrobianos basados en el consumo**  
FARMACIA HOSPITALARIA  
<https://bit.ly/2HfMIRU>
- **Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent *Clostridium difficile* Infection: A Systematic Review and Meta-analysis**  
CLINICAL INFECTIOUS DISEASES  
<https://bit.ly/2YliH7l>
- **Current Treatment Options for Acute Skin and Skin-structure Infections**  
CLINICAL INFECTIOUS DISEASES  
<https://bit.ly/2GqK3it>
- **Long-acting Opioid Use and the Risk of Serious Infections: A Retrospective Cohort Study**  
CLINICAL INFECTIOUS DISEASES  
<https://bit.ly/30UQli9>
- **Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial**  
CLINICAL INFECTIOUS DISEASES  
<https://bit.ly/30ONBTt>

- **Early Oral Switch to Linezolid for Low-risk Patients With *Staphylococcus aureus* Bloodstream Infections: A Propensity-matched Cohort Study**  
CLINICAL INFECTIOUS DISEASES  
<https://bit.ly/2Y9NUX1>
- **Role of Early De-escalation of Antimicrobial Therapy on Risk of *Clostridioides difficile* Infection Following Enterobacteriaceae Bloodstream Infections**  
CLINICAL INFECTIOUS DISEASES  
<https://bit.ly/2SykX5V>
- **Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated pneumonia**  
ANTIMICROBIAL RESISTANCE & INFECTION CONTROL  
<https://bit.ly/2GnJkhW>
- **The Potential for QT Interval Prolongation with Chronic Azithromycin Therapy in Adult Cystic Fibrosis Patients**  
PHARMACOTHERAPY  
<https://bit.ly/2y3A4uH>
- **Four Decades of  $\beta$ -Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis**  
CLINICAL PHARMACOKINETICS  
<https://bit.ly/2Mda0WB>
- **Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?**  
EUROPEAN JOURNAL OF CLINICAL PHARMACOTHERAPY  
<https://bit.ly/2LBZuZt>
- **Impact of a pharmacist-driven education initiative on treatment of asymptomatic bacteriuria**  
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY  
<https://bit.ly/2K4dJmz>
- **Ceftazidime stability and pyridine toxicity during continuous i.v. infusion**  
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY  
<https://bit.ly/2M7vJ23>
- **Activity of imipenem/relebactam against MDR *Pseudomonas aeruginosa* in Europe: SMART 2015–17**  
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY  
<https://bit.ly/2M4ISJ0>
- **Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy**  
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY  
<https://bit.ly/2JTalFm>

- **Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trial**  
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY  
<https://bit.ly/2SAb0F7>
- **Defining optimal dosing of ciprofloxacin in patients with septic shock**  
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY  
<https://bit.ly/2M9ieyP>
- **Evaluation of a pharmacist-led penicillin allergy de-labelling ward round: a novel antimicrobial stewardship intervention**  
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY  
<https://bit.ly/32MQndv>
- **Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience**  
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS  
<https://bit.ly/2JKK2YA>
- **Use of non-carbapenem antibiotics to treat severe extended-spectrum  $\beta$ -lactamase-producing Enterobacteriaceae infections in intensive care unit patients**  
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS  
<https://bit.ly/2XY4FJy>
- **Activity of ceftolozane/tazobactam against *Pseudomonas aeruginosa* and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study**  
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS  
<https://bit.ly/32MVkDI>
- **Fluoroquinolone-based versus  $\beta$ -lactam-based regimens for complicated intra-abdominal infections: a meta-analysis of randomised controlled trials**  
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS  
<https://bit.ly/2JK42KZ>
- **$\beta$ -lactam antibiotics vs. vancomycin for the early treatment of enterococcal bacteraemia: A retrospective cohort study**  
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS  
<https://bit.ly/30QaENz>
- **Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials**  
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS  
<https://bit.ly/2Y1qLEM>

- **A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-*Staphylococcus aureus* Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers**  
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY  
<https://bit.ly/30RNG8U>
- **Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections**  
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY  
<https://bit.ly/2SA40rT>
- **Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin Resistant *Staphylococcus aureus* Bacteremia**  
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY  
<https://bit.ly/2XVxGWi>
- **A Systematic Review and Meta-analysis of Antibiotic Treatment Duration for Bacteremia Due to *Enterobacteriaceae***  
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY  
<https://bit.ly/30QVhV5>
- **Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with *Staphylococcus aureus* bacteraemia**  
CLINICAL MICROBIOLOGY AND INFECTION  
<https://bit.ly/2LCLD4Y>
- **Fidaxomicin versus oral vancomycin for severe *Clostridium difficile* infection: a retrospective cohort study**  
CLINICAL MICROBIOLOGY AND INFECTION  
<https://bit.ly/2SChGTI>
- **Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing *Enterobacteriaceae* in different groups of patient**  
CLINICAL MICROBIOLOGY AND INFECTION  
<https://bit.ly/2JNejGp>

## Guías de práctica clínica, documentos consenso

- **ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers.**  
<https://bit.ly/2Oeabn5>

- **Executive summary of outpatient parenteral antimicrobial therapy: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases and the Spanish Domiciliary Hospitalization Society**  
Enfermedades infecciosas y microbiología clínica  
<https://bit.ly/2Y1ppQS>
- **GUIA NICE 2019: surgical site infection: prevention and treatment**  
<https://bit.ly/2X6PWY7>

## Alertas farmacéuticas, notas informativas

### ANTIBIOTICOS EN EVALUACION POR LA EMA. UNAS PINCELADAS:

- **DELAFLORACINO**
  - DIANA: *S. Aureus* (SAMS y SAMR CMI  $\leq 5$  mg/L), Estreptococos (neumococo, incluso si resistente a fluorquinolonas), Haemophilus Influenzae, Enterobacterias, Pseudomonas.
  - NO ACTIVIDAD: Enterococo faecium, Enterobacterias BLEE, Acinetobacter, bacilos gram negativos resistentes a fluorquinolonas
  - Posología: 450 mg/12h ORAL, 300 mg/12h IV.
- **IMIPENEM, CILASTATINA AND RELEBACTAM (APROVADO POR FDA EN 2019):** Combinación de carbapenem con inhibidor de dihidropeptidasa renal (cilastatina) e inhibidor de betalactamasa (relebactam). De forma general, se considera activo frente a BLEE, AMPc, KPC, MLB y algo menos activo frente a OXA-48.
- **LEFAMULIN:** Lefamulin es un antibiótico de pleuromutilina semisintético, primero en su clase, en desarrollo para el tratamiento de la neumonía bacteriana adquirida en la comunidad. Es un inhibidor de la síntesis proteica a través de un mecanismo novedoso. Existe presentación oral e IV.
  - DIANA: *S. Aureus*, Estreptococos (neumococos) , enterococo resistente a vancomicina
  - También activo frente a otros agentes causantes de infecciones respiratorias como Haemophilus influenzae, Mycoplasma pneumoniae, Legionella pneumophila, y Chlamydomphila pneumoniae
- **CEFIDEROCOL:** cefalosporina siderófora, se une al hierro sérico y se transporta activamente a las células bacterianas a través de la membrana externa mediante los transportadores de hierro bacterianos. Más estable frente a la hidrólisis de todas las betalactamasas. Amplio espectro de patógenos Gram-negativos, incluyendo Acinetobacter baumannii resistente a carbapenem, Pseudomonas aeruginosa, Stenotrophomonas maltophilia y Enterobacteriaceae (CRE). De forma general es activo frente a BLEE, AMPc, KPC, OXA-48 y MBL

- PLAZOMICINA: Nueva generación de aminoglucósido. De forma general es activo frente BLEE, AMPc, KPC, OXA-48 (menor actividad) y MBL (no NDM). Tiene resistencia intrínseca a *Providencia stuarti*).

- Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use. July 2019

<https://bit.ly/3oTolLO>

- Novedades terapéuticas para el tratamiento de infecciones causadas por Gram positivos y Gram negativos. Jornada Grupo AFinf. Actualización en atención farmacéutica de enfermedades infecciosas 2017.

## Boletín AEMPS mensual Abril 2019

- Quinolonas y fluoroquinolonas de uso sistémico: riesgo de reacciones adversas incapacitantes, de duración prolongada y potencialmente irreversibles y restricciones de uso

<https://bit.ly/2JL2Dnj>

## IPT

Informe de Posicionamiento Terapéutico de levofloxacin (Quinsair®) en infección crónica por *Pseudomonas aeruginosa* en fibrosis quística

<https://bit.ly/2LGyXtK>

Informe de Posicionamiento Terapéutico de letermovir (Prevymis®) en la profilaxis de la reactivación del CMV y de la enfermedad causada por este virus en adultos seropositivos para el CMV [R+] receptores de un TCMH

<https://bit.ly/2ZjrdAT>

## Informacion a pacientes

- Necrotizing Soft Tissue Infections  
JAMA Patient Page describe para los pacientes los síntomas el diagnóstico y el tratamiento de infecciones necrotizantes de piel y partes blandas


<https://bit.ly/2Ze2WN6>

- Home Intravenous Antibiotic Therapy  
JAMA Patient Page describe para los pacientes la administración domiciliar de antibioterapia


<https://bit.ly/2JXXvLC>

## APPs


- Guía Terapéutica Antibiótica Son Espases**  
 Disponible Apple Store y Google play para Android  
 App gratuita



- Sandford Guide antimicrobial**  
 Disponible Apple Store y Google play para Android  
 Ofrece compras dentro de la App




- Johns Hopkins Antibiotic Guide**  
 Disponible Apple Store y Google play para Android  
 Ofrece compras dentro de la App




- **Microguide**

Disponible Apple Store y Google play para Android  
App gratuita



- **Guía Mensa**

Disponible Apple Store  
Ofrece compras dentro de la App



**Autores:** Elena Sánchez Yáñez, Marcelo Domínguez Cantero, Svetlana Sadyrbaeva, Edurne Fernández de Gamarra Martínez,

**Editado por:** Grupo de Trabajo Atención Farmacéutica en Enfermedades Infecciosas de la Sociedad Española de Farmacia Hospitalaria C/ Rafael del Riego, 38 28045 Madrid

**Tel:** +34 91 571 44 87 **Fax:** +34 91 571 45 86 **Email:** [sefh@sefh.es](mailto:sefh@sefh.es)

**Web:** <http://gruposdetrabajo.sefh>

**ISSN:** 2445-2882